WAT Stock: Price, Earnings History and SEC Filings
Waters Corporation (WAT) last traded at $462.72, down 3.61% on the latest session and up 5.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $3.05 against an analyst estimate of $3.01, a beat of 1.3%.
$462.72 -3.61%
1 month+5.31%
52-week high$482.28
52-week low$282.77
Volume1.34M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
WAT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $3.05 | $3.01 | +1.33% |
| Mar 2026 | May 5, 2026 | $2.70 | $2.31 | +16.88% |
| Dec 2025 | Feb 9, 2026 | $4.53 | $4.50 | +0.67% |
| Sep 2025 | Nov 4, 2025 | $3.40 | $3.21 | +5.92% |
WAT beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for WAT
SEC filing data is not available right now. You can search for WAT on SEC EDGAR.
WAT news
- Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug SafetyOct 29, 2026 · finance.yahoo.com
- Waters Gears Up to Report Q3 Results: How to Play the Stock?Oct 28, 2026 · finance.yahoo.com
- Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower SoftwareOct 28, 2026 · finance.yahoo.com
- Waters & Labcorp Expand Access to FDA-Approved HPV Screening TestsOct 27, 2026 · finance.yahoo.com
- 2 Reasons to like WAT and 1 to stay skepticalOct 26, 2026 · finance.yahoo.com
- 1 healthcare stock for long-term investors and 2 we ignoreOct 26, 2026 · finance.yahoo.com
- Quest Diagnostics (DGX) Backs At Home Cervical Cancer ScreeningOct 23, 2026 · finance.yahoo.com
- Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026Oct 23, 2026 · finance.yahoo.com
About Waters Corporation
Waters Corporation (WAT) is a US-listed public company on NYSE.